Nothing Special   »   [go: up one dir, main page]

PL1833799T3 - 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem - Google Patents

3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem

Info

Publication number
PL1833799T3
PL1833799T3 PL05849546T PL05849546T PL1833799T3 PL 1833799 T3 PL1833799 T3 PL 1833799T3 PL 05849546 T PL05849546 T PL 05849546T PL 05849546 T PL05849546 T PL 05849546T PL 1833799 T3 PL1833799 T3 PL 1833799T3
Authority
PL
Poland
Prior art keywords
modulators
phenyl
treatment
disorders related
serotonin receptor
Prior art date
Application number
PL05849546T
Other languages
English (en)
Inventor
Bradley Teegarden
Yifeng Xiong
Sonja Strah-Pleynet
Honnappa Jayakumar
Peter I Dosa
Konrad Feichtinger
Martin Casper
Juerg Lehmann
Robert M Jones
David J Unett
Jin Sun Karoline Choi
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of PL1833799T3 publication Critical patent/PL1833799T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05849546T 2004-11-19 2005-11-17 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem PL1833799T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62977404P 2004-11-19 2004-11-19
US64763905P 2005-01-26 2005-01-26
US65838405P 2005-03-02 2005-03-02
US71338405P 2005-09-01 2005-09-01
US73316505P 2005-11-04 2005-11-04
EP05849546A EP1833799B1 (en) 2004-11-19 2005-11-17 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
PCT/US2005/041726 WO2006055734A2 (en) 2004-11-19 2005-11-17 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
PL1833799T3 true PL1833799T3 (pl) 2009-02-27

Family

ID=36218810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05849546T PL1833799T3 (pl) 2004-11-19 2005-11-17 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem

Country Status (37)

Country Link
US (6) US20070244086A1 (pl)
EP (2) EP1978019A1 (pl)
JP (1) JP5016494B2 (pl)
KR (2) KR101275380B1 (pl)
CN (3) CN103012378A (pl)
AR (1) AR051675A1 (pl)
AT (1) ATE407927T1 (pl)
AU (1) AU2005307744C1 (pl)
BR (1) BRPI0518446A2 (pl)
CA (1) CA2588513C (pl)
CR (1) CR9098A (pl)
CY (1) CY1108508T1 (pl)
DE (1) DE602005009748D1 (pl)
DK (1) DK1833799T3 (pl)
EA (1) EA011935B1 (pl)
ES (1) ES2314750T3 (pl)
GT (1) GT200500336A (pl)
HK (1) HK1102818A1 (pl)
HN (1) HN2005032627A (pl)
HR (1) HRP20080592T3 (pl)
IL (1) IL182945A (pl)
MA (1) MA29081B1 (pl)
MX (1) MX2007005959A (pl)
MY (1) MY147684A (pl)
NI (1) NI200700127A (pl)
NO (1) NO340656B1 (pl)
NZ (1) NZ554817A (pl)
PE (1) PE20061130A1 (pl)
PL (1) PL1833799T3 (pl)
PT (1) PT1833799E (pl)
RS (1) RS50698B (pl)
SA (1) SA05260357B1 (pl)
SI (1) SI1833799T1 (pl)
SV (1) SV2008002307A (pl)
TN (1) TNSN07188A1 (pl)
TW (2) TWI409062B (pl)
WO (1) WO2006055734A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
CN1926114B (zh) * 2004-03-23 2011-08-24 艾尼纳制药公司 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
CN101479261A (zh) 2006-05-18 2009-07-08 艾尼纳制药公司 3-吡唑基-苯甲酰胺-4-醚、其仲胺及其衍生物作为5-ht2a血清素受体的调节剂用于治疗与其相关的病症
MY154962A (en) 2006-05-18 2015-08-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
WO2008027483A1 (en) * 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008054748A2 (en) * 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
ES2483366T3 (es) 2007-12-13 2014-08-06 Vanda Pharmaceuticals Inc. Método y composición para el tratamiento de una afección mediada por el receptor de serotonina
US8729100B2 (en) * 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
LT2364142T (lt) 2008-10-28 2018-06-25 Arena Pharmaceuticals, Inc. 5-ht2a serotonino receptoriaus moduliatoriaus kompozicijos, naudotinos su juo susijusių sutrikimų gydymui
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2011075596A1 (en) * 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP3028683B1 (en) 2011-07-14 2018-05-09 Cook Medical Technologies LLC A kit to be used in the treatment of obstructive sleep apnea
EP2908770B1 (en) 2012-10-16 2019-04-24 Cook Medical Technologies LLC Apparatus for treating obstructive sleep apnea (osa)
EP3498239B1 (en) 2013-08-01 2021-04-21 Cook Medical Technologies LLC Tissue adjustment implant
CN105392433B (zh) 2013-08-05 2019-02-19 库克医学技术有限责任公司 具有可释放管状构件的医疗装置及其使用方法
CN104906682A (zh) 2014-01-24 2015-09-16 史蒂文·沙勒布瓦 铰接气囊导管及其使用方法
US9974563B2 (en) 2014-05-28 2018-05-22 Cook Medical Technologies Llc Medical devices having a releasable member and methods of using the same
EP3177219B1 (en) 2014-08-04 2018-09-26 Cook Medical Technologies LLC Medical devices having a releasable tubular member
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2019006218A1 (en) 2017-06-29 2019-01-03 Oconnor Peter MEDICAL DEVICES IMPLANTABLE TO REPOSITION A FABRIC
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
EP3710441A1 (en) * 2017-11-17 2020-09-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SLEEP ENHANCEMENT SYSTEM AND METHOD
JP2024502821A (ja) * 2020-12-31 2024-01-23 アリーナ ファーマシューティカルズ, インコーポレイテッド 処置方法
EP4452986A1 (en) * 2021-12-22 2024-10-30 Kuleon LLC Serotonin receptor agonists and methods of making and using the same
WO2024122617A1 (ja) * 2022-12-08 2024-06-13 塩野義製薬株式会社 セロトニン受容体結合活性を有する含窒素複素環および炭素環誘導体

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
DE2926517A1 (de) * 1979-06-30 1981-01-15 Beiersdorf Ag Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5661024A (en) 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
EP0714389B1 (en) * 1993-08-20 1998-06-17 Smithkline Beecham Plc Amide and urea derivatives as 5ht1d receptor antagonists
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
JPH10510512A (ja) 1994-10-04 1998-10-13 藤沢薬品工業株式会社 尿素誘導体とacat阻害剤としての用途
NZ301265A (en) * 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
WO1997045111A1 (en) 1996-05-24 1997-12-04 Neurosearch A/S Phenyl derivatives useful as blockers of chloride channels
DE69716424T2 (de) * 1996-05-24 2003-02-20 Neurosearch A/S, Ballerup Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
TR199802695T2 (xx) * 1996-06-27 1999-04-21 Smithkline Beecham Corporation IL-8 Resept�r kar��tlar�
JP2001508767A (ja) * 1996-12-02 2001-07-03 藤沢薬品工業株式会社 5―ht拮抗作用を有するインドール―ウレア誘導体
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
ATE248824T1 (de) * 1997-04-22 2003-09-15 Neurosearch As Substituierte phenylderivate, ihre herstellung und verwendung
JP2001512096A (ja) 1997-07-29 2001-08-21 スミスクライン・ビーチャム・コーポレイション Il−8レセプターアンタゴニスト
PT1027328E (pt) * 1997-10-31 2006-11-30 Aventis Pharma Ltd Anilidas substituídas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ID26956A (id) 1997-12-22 2001-02-22 Bayer Ag Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害
CA2325559A1 (en) 1998-04-14 1999-10-21 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) * 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
KR100799892B1 (ko) * 1998-10-22 2008-01-31 뉴로서치 에이/에스 치환된 페닐 유도체 및 이를 포함하는 약제학적 조성물
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
AR023171A1 (es) 1999-03-26 2002-09-04 Cocensys Inc Pirazoles, imidazoles, oxazoles, tiazoles, y pirroles sustituidos por arilo, y el uso de los mismos.
GB9909409D0 (en) 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
EP1108720A1 (en) 1999-12-08 2001-06-20 Basf Aktiengesellschaft Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002223492A1 (en) 2000-11-14 2002-05-27 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AR035521A1 (es) 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
WO2002076464A1 (en) 2001-03-22 2002-10-03 Arena Pharmaceuticals, Inc. Anti-psychosis combination
RS51444B (sr) * 2001-09-21 2011-04-30 Bristol-Myers Squibb Company JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
WO2003062206A2 (en) * 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2003275093A1 (en) 2002-09-24 2004-04-19 Arena Pharmaceuticals, Inc. Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof
US7016330B2 (en) 2002-11-08 2006-03-21 Interdigital Technology Corporation Composite channel quality estimation techniques for wireless receivers
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
MXPA05010496A (es) 2003-03-28 2005-11-16 Pharmacia & Upjohn Co Llc Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
MXPA06000795A (es) * 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CN1926114B (zh) * 2004-03-23 2011-08-24 艾尼纳制药公司 用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
JP2008509982A (ja) 2004-08-16 2008-04-03 プロシディオン・リミテッド アリール尿素誘導体
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP2008518014A (ja) 2004-10-27 2008-05-29 ニューロゲン コーポレイション Cb1拮抗薬としてのジアリール尿素
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
PE20061130A1 (es) * 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
AR051978A1 (es) 2004-12-01 2007-02-21 Divergence Inc Composiciones plaguicidas y metodos
US20080015223A1 (en) * 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
WO2006070394A1 (en) 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
EP1858877B1 (en) 2005-01-14 2014-03-12 Gilead Connecticut, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
CA2594563A1 (en) 2005-01-19 2006-07-27 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
AR052886A1 (es) 2005-01-26 2007-04-11 Arena Pharm Inc Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
KR101332218B1 (ko) 2005-01-27 2013-11-25 얀센 파마슈티카 엔.브이. Cns 질환의 치료시의 5ht2 저해제로서의헤테로사이클릭 테트라사이클릭 테트라하이드로푸란 유도체
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
GB0505725D0 (en) 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
ES2340066T3 (es) 2005-04-26 2010-05-28 Hypnion, Inc. Compuestos de benzisoxazol piperidina y procedimiento de uso de los mismos.
EP1734039A1 (en) 2005-06-13 2006-12-20 Esbatech AG Aryl urea compounds as BETA-secretase inhibitors
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
EP2004627A2 (en) 2006-04-10 2008-12-24 Arena Pharmaceuticals, Inc. 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0608655D0 (en) 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
MY154962A (en) 2006-05-18 2015-08-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
CN101479261A (zh) * 2006-05-18 2009-07-08 艾尼纳制药公司 3-吡唑基-苯甲酰胺-4-醚、其仲胺及其衍生物作为5-ht2a血清素受体的调节剂用于治疗与其相关的病症
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
EP2051978A2 (en) 2006-05-18 2009-04-29 Arena Pharmaceuticals, Inc. Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2008027483A1 (en) 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008054748A2 (en) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
JP2009196349A (ja) * 2008-01-25 2009-09-03 Canon Finetech Inc バーコード印刷装置およびバーコード印刷方法
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Also Published As

Publication number Publication date
AU2005307744C1 (en) 2011-11-24
EP1833799B1 (en) 2008-09-10
CA2588513A1 (en) 2006-05-26
MX2007005959A (es) 2007-07-04
NO20072986L (no) 2007-08-20
DK1833799T3 (da) 2009-01-19
JP5016494B2 (ja) 2012-09-05
KR20070086357A (ko) 2007-08-27
CA2588513C (en) 2013-08-06
GT200500336A (es) 2006-06-22
HRP20080592T3 (en) 2009-01-31
PT1833799E (pt) 2008-12-12
US20110105456A1 (en) 2011-05-05
US20070207994A1 (en) 2007-09-06
WO2006055734A3 (en) 2006-08-17
CN101084195B (zh) 2013-01-02
WO2006055734A2 (en) 2006-05-26
HK1102818A1 (en) 2007-12-07
ES2314750T3 (es) 2009-03-16
TNSN07188A1 (en) 2008-11-21
US20070244086A1 (en) 2007-10-18
PE20061130A1 (es) 2007-01-05
TW200618798A (en) 2006-06-16
TWI377059B (en) 2012-11-21
NO340656B1 (no) 2017-05-22
AU2005307744B2 (en) 2011-06-09
ATE407927T1 (de) 2008-09-15
JP2008520695A (ja) 2008-06-19
AU2005307744B8 (en) 2011-08-04
BRPI0518446A2 (pt) 2008-11-18
US20160304463A1 (en) 2016-10-20
EP1833799A2 (en) 2007-09-19
TWI409062B (zh) 2013-09-21
KR20130027039A (ko) 2013-03-14
KR101275380B1 (ko) 2013-06-25
CN102977029A (zh) 2013-03-20
SV2008002307A (es) 2008-02-08
TW201231052A (en) 2012-08-01
NZ554817A (en) 2011-01-28
CN101084195A (zh) 2007-12-05
NI200700127A (es) 2008-06-05
AU2005307744A1 (en) 2006-05-26
MA29081B1 (fr) 2007-12-03
US20190263757A1 (en) 2019-08-29
IL182945A0 (en) 2007-09-20
CN102977029B (zh) 2017-12-19
CR9098A (es) 2008-02-21
CY1108508T1 (el) 2014-04-09
SI1833799T1 (sl) 2009-02-28
MY147684A (en) 2012-12-31
HN2005032627A (es) 2010-08-19
CN103012378A (zh) 2013-04-03
EA011935B1 (ru) 2009-06-30
EP1978019A1 (en) 2008-10-08
US8785441B2 (en) 2014-07-22
SA05260357B1 (ar) 2008-09-08
RS50698B (sr) 2010-06-30
US20130237540A1 (en) 2013-09-12
IL182945A (en) 2012-06-28
AR051675A1 (es) 2007-01-31
US7884101B2 (en) 2011-02-08
DE602005009748D1 (de) 2008-10-23
EA200701101A1 (ru) 2007-12-28
US10781180B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
PT1833799E (pt) Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas
HK1121448A1 (en) Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto 5-th2a
ZA200802608B (en) Pharmaceutical compositions of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
ZA200609234B (en) Substituted azeplne derivatives as serotonin receptor modulators
IL182685A0 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
IL185016A0 (en) Compounds for the treatment of proliferative disorders
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
IL182365A0 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
HUE036506T2 (hu) 5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére
IL179609A0 (en) Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
PT2418201E (pt) Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central
HK1121453A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor 5-ht2a
ZA200700684B (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
ZA200703389B (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
IL188856A0 (en) Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases
ZA200703060B (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to odulation of the dopamine d3 receptor
PL1737820T3 (pl) Sposób asymetrycznego uwodorniania nadający się do wytwarzania pochodnych cykloalkanoindoli
ZA200703201B (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
ZA200703885B (en) 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
ZA200808813B (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
GB0408297D0 (en) Indole derivatives for the treatment of diseases